Literature DB >> 19260529

[A rapidly progressed metastatic choroidal tumor from a hepatocellular carcinoma].

Hiroko Tateno1, Takeshi Hoshino, Kanji Takahashi, Miyo Matsumura, Noriko Sakaida, Chisato Ohe.   

Abstract

BACKGROUND: Metastatic choroidal tumor stemming from a hepatocellular carcinoma (HCC) is very rare. We report a case of a metastatic choroidal tumor stemming from a hepatocellular carcinoma. CASE: A 50-year-old man became aware of a visual field defect in his left eye starting 1 month previously. He had undergone surgery for HCC nine years before, and had received radiation therapy for lung and brain metastasis of HCC. Funduscopic examination revealed a red choroidal mass with subretinal bleeding. One month later, light perception of the left eye disappeared with rapid growth of the tumor and high intraocular pressure. Because the ocular pain was uncontrollable, enucleation of the left eyeball was performed. In histopathological examination, the choroidal tumor consisted of tumor cells showing characteristics of HCC such as intracytoplasmic glycogen granules, fatty degeneration, and necrosis of the tumor cells.
CONCLUSION: The clinical characteristics of metastatic choroidal tumors from an HCC are a red appearance and rapid growth with retinal detachment and subretinal hemorrhage.

Entities:  

Mesh:

Year:  2009        PMID: 19260529

Source DB:  PubMed          Journal:  Nippon Ganka Gakkai Zasshi        ISSN: 0029-0203


  2 in total

1.  Choroidal metastasis from hepatocellular carcinoma, diagnosed by fine needle aspiration biopsy and treated by iodine-125 brachytherapy.

Authors:  Lalkrushna Malaviya; Carol L Shields; Kiran Turaka; Hormoz Ehya; Jerry A Shields
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-02-09       Impact factor: 3.117

2.  Retrobulbar metastasis and intracranial invasion from postoperative hepatocellular carcinoma: A case report and review of the literature.

Authors:  Chun-Yong Chen; Jian-Hong Zhong; Jing-Li Liu
Journal:  Oncol Lett       Date:  2014-11-24       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.